Generex Biotechnology Partner Olaregen Therapeutix Inc. Establishes Sales Force and Distribution Team for the Commercial Launch of Excellagen
Business Wire Business Wire•December 20, 2018
MIRAMAR, Fla.--(BUSINESS WIRE)--
150+ Wound care consultants the core of national launch of Excellagen for the treatment of surgical wounds, diabetic foot ulcers, venous skin ulcers, and other hard to treat wounds
Contract with VA system through Service-Disabled Veteran-Owned Small Business (SDVOSB) network
Generex Biotechnology Corporation (GNBT) is pleased to announce that their partially-owned, but soon to be wholly-owned subsidiary, Olaregen Therapeutix has established a premier sales force in the wound care space and contracted with a Service-Disabled Veteran-Owned Small Business (SDVOSB) for distribution of Excellagen in the VA system through a network of veteran-owned distribution partners.
Olaregen CEO Anthony J. Dolisi commented, “Through a dedicated recruiting effort with our sales channel partners, we are building an expert sales force with extensive experience in medical sales and wound care. Olaregen now has 150+ Sales Consultants who are poised to successfully commercialize Excellagen by delivering outstanding and connected customer service. At Olaregen, we view customer support as an integral part of our mission to heal challenging wounds with cutting-edge regenerative medicine products like Excellagen, which is a novel cellular and tissue based product (CTP). CTPs are of particular benefit to chronic non-healing wounds as they work to stimulate wound healing by utilizing the patient’s own cells to rebuild tissues. We are pleased to have a dedicated sales force poised to launch Excellegen in the multi-billion wound care market in the first quarter of 2019.”
Olaregen provides a comprehensive sales training program for the sales team, including:
A comprehensive module on wound development and progression, with detailed training on the use of Excellegen for the treatment and management of hard to manage wounds;
Compliance training and education for all team members to promote organizational adherence to applicable federal and state law, and private payer healthcare requirements;
Implementation of standard operating procedures (SOPs) to identify and eliminate fraud, waste, and abuse;
Internal and external controls for sales tracking, verification, and validation.
In addition to these critical sales efforts, Olaregen is developing strategic relationships within the Government Services Administration (GSA) through a SDVOSB that maintains a network of veteran-owned marketing and distribution organizations that have preferred contractor status throughout the 21 Veteran Integrated Services Network (VISN) regions.
About Generex Biotechnology
Generex is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, medical devices, and pharmaceutical development. The Company’s direct-to-patient services support its strategy of all-inclusive access to doctors, diagnostics, therapeutics, and additional health-related services to greatly improve the patient experience in receiving care. On the provider side, Generex’s management services remove administrative burdens in multiple provider settings, including private practice and hospital, allowing doctors to devote more time to patient care. Revenue from the Company’s subsidiaries will support clinical advancement of its wholly owned therapeutic products with a focus on regenerative medicine, immunotherapy, and diabetes management.
Business Wire Business Wire•December 20, 2018
MIRAMAR, Fla.--(BUSINESS WIRE)--
150+ Wound care consultants the core of national launch of Excellagen for the treatment of surgical wounds, diabetic foot ulcers, venous skin ulcers, and other hard to treat wounds
Contract with VA system through Service-Disabled Veteran-Owned Small Business (SDVOSB) network
Generex Biotechnology Corporation (GNBT) is pleased to announce that their partially-owned, but soon to be wholly-owned subsidiary, Olaregen Therapeutix has established a premier sales force in the wound care space and contracted with a Service-Disabled Veteran-Owned Small Business (SDVOSB) for distribution of Excellagen in the VA system through a network of veteran-owned distribution partners.
Olaregen CEO Anthony J. Dolisi commented, “Through a dedicated recruiting effort with our sales channel partners, we are building an expert sales force with extensive experience in medical sales and wound care. Olaregen now has 150+ Sales Consultants who are poised to successfully commercialize Excellagen by delivering outstanding and connected customer service. At Olaregen, we view customer support as an integral part of our mission to heal challenging wounds with cutting-edge regenerative medicine products like Excellagen, which is a novel cellular and tissue based product (CTP). CTPs are of particular benefit to chronic non-healing wounds as they work to stimulate wound healing by utilizing the patient’s own cells to rebuild tissues. We are pleased to have a dedicated sales force poised to launch Excellegen in the multi-billion wound care market in the first quarter of 2019.”
Olaregen provides a comprehensive sales training program for the sales team, including:
A comprehensive module on wound development and progression, with detailed training on the use of Excellegen for the treatment and management of hard to manage wounds;
Compliance training and education for all team members to promote organizational adherence to applicable federal and state law, and private payer healthcare requirements;
Implementation of standard operating procedures (SOPs) to identify and eliminate fraud, waste, and abuse;
Internal and external controls for sales tracking, verification, and validation.
In addition to these critical sales efforts, Olaregen is developing strategic relationships within the Government Services Administration (GSA) through a SDVOSB that maintains a network of veteran-owned marketing and distribution organizations that have preferred contractor status throughout the 21 Veteran Integrated Services Network (VISN) regions.
About Generex Biotechnology
Generex is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, medical devices, and pharmaceutical development. The Company’s direct-to-patient services support its strategy of all-inclusive access to doctors, diagnostics, therapeutics, and additional health-related services to greatly improve the patient experience in receiving care. On the provider side, Generex’s management services remove administrative burdens in multiple provider settings, including private practice and hospital, allowing doctors to devote more time to patient care. Revenue from the Company’s subsidiaries will support clinical advancement of its wholly owned therapeutic products with a focus on regenerative medicine, immunotherapy, and diabetes management.
